Rosecliff Acquisition Corp I: management transactions · United States · SEC (Form 4)

About Rosecliff Acquisition Corp I

Rosecliff Acquisition Corp I is a U.S.-based special purpose acquisition company (SPAC), meaning it was formed primarily to execute a business combination rather than operate a conventional commercial business. The company was incorporated in Delaware on November 17, 2020, and it came to the public markets on Nasdaq under the ticker RCLF. For investors, that distinction matters: Rosecliff was a capital-markets vehicle designed to identify, negotiate, and complete a merger, stock exchange, asset acquisition, reorganization, or similar transaction in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833498/000121390022016396/f10k2021_rosecliffacq1.htm?utm_source=openai)) Its corporate history follows the typical U.S. SPAC playbook seen in the 2020–2021 issuance wave. Rosecliff completed its IPO in February 2021, selling units at $10.00 each and raising gross proceeds of about $253 million. As with most SPACs, the structure included a sponsor entity, Rosecliff Acquisition Sponsor I LLC, together with founder shares, private warrants, and a trust account framework intended to protect public investors until a target was identified. The sponsor and management team were central to the economics of the vehicle, because their value creation depended on sourcing and closing an attractive transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833498/000121390022016396/f10k2021_rosecliffacq1.htm?utm_source=openai)) In competitive terms, Rosecliff operated in one of the most crowded segments of the U.S. capital markets. SPAC performance depends less on proprietary products and more on deal execution: the ability to find a credible target, negotiate terms, manage redemptions, and complete a transaction that the market can support. Rosecliff’s most notable business-development milestone was its announced combination with Spectral MD Holdings, an AI-enabled medical diagnostics company. That proposed transaction positioned the SPAC toward a health-tech growth theme, and SEC filings indicate that the combined company structure would leave the operating business as the dominant post-closing asset. ([nasdaq.com](https://www.nasdaq.com/press-release/spectral-md-holdings-ltd.-an-fda-breakthrough-designated-company-focused-on?utm_source=openai)) Geographically, the company is tied to the United States and the U.S. listed-equity ecosystem, with Nasdaq as the relevant exchange reference. Because Rosecliff is not a traditional operating company, it does not have a recurring catalog of products or services; its “business line” is effectively transaction origination and SPAC structuring. Recent milestones therefore center on merger documentation, SEC filings, and post-combination structural updates rather than customer growth, revenue expansion, or product launches. For a French-speaking investor base, Rosecliff should be viewed as a financial engineering vehicle whose market relevance came from the quality of the target it brought to public markets, not from standalone industrial operations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1833498/000121390025026157/R8.htm?utm_source=openai))